×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Neuroendocrine Cancer
Kristie L. Kahl
From celebrity news to a new partnership aimed to help patients and their caregivers, here’s what is making headlines in the cancer space this week.
Tracey M. Hopkins
This essay was written by Tracey M. Hopkins nominating registered nurse Rubirosa Ison, St. Joseph’s Hospital-North, Lutz, Florida, for CURE®’s 2019 Extraordinary Healer® Award.
Expert oncologist Robert Ramirez, DO, FACP, provides his perspective on the recent advances in identifying and managing neuroendocrine tumors that have improved the overall treatment of this complex disease.
Both Francisca Bellard and Sylvia Lubrano provide their perspective on the importance of self-advocacy and education for patients who are diagnosed and treated for neuroendocrine tumors.
Expert oncologist Robert Ramirez, DO, FACP, shares practical advice for patients with diagnosed neuroendocrine tumors regarding the importance of quality of life and self-advocacy throughout the treatment journey.
Francisca Bellard describes her truly remarkable response following multivisceral transplant and shares what life has been like after her successful treatment.
Francisca Bellard reflects on her experience of waiting for, and undergoing, a multivisceral transplant to remove her neuroendocrine disease.
Francisca Bellard discusses her initial consultations with Dr. Ramirez and reflects on the challenges she faced while preparing to undergo her multivisceral transplant.
Francisca Bellard shares the story of her initial treatment for a neuroendocrine tumor following a very sudden and daunting diagnosis and prognosis.
Sylvia Lubrano describes her experience with somatostatin analogs, particularly regarding her switch from octreotide long acting to lanreotide.